Kiniksa Pharmaceuticals Ltd expected to post a loss of 41  cents a share - Earnings Preview

Kiniksa Pharmaceuticals International

29/04/2022 17:05

* Kiniksa Pharmaceuticals Ltd  KNSA.OQ   KNSA.O  is expected
to show a rise in quarterly revenue when it reports  results on
May 2 (estimated). 
    * The Hamilton Bermuda-based   company is expected to report
revenue of $22.77 million, according to the mean estimate from 3
analysts, based on Refinitiv data.  
    * ​Refinitiv's mean analyst estimate for Kiniksa
Pharmaceuticals
Ltd is for a loss of 41 cents per share. For the same quarter
last year, the company reported a loss of 72 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 1.2%
in the last three months. ​
    * Wall Street's median 12-month price target for Kiniksa
Pharmaceuticals Ltd is $24​, above​ its last closing price
of $9.77. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2021  -0.42       -0.42      -0.53     Missed  -26.2
 Sep. 30 2021  -0.65       -0.65      -0.44     Beat    32
 Jun. 30 2021  -0.94       -0.79      -0.61     Beat    23​
 Mar. 31 2021  -0.63       -0.72      -0.72     Met     0.7
 ​​Dec.        -0.61       -0.62      -0.79     Missed  -26.9
 31 2020                                                
 Sep. 30 2020  -0.60       -0.60      -0.66     Missed  -9.1​
 Jun. 30 2020  -0.60       -0.63      -0.65     Missed  -3.8
 Mar. 31 2020  -0.67       -0.63      -0.48     Beat    24.3
 This summary was machine generated April 29 at 16:05 GMT.  All
figures in US dollars  unless otherwise stated